U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H18N2O3S
Molecular Weight 354.423
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of ST-638

SMILES

CCOC1=C(O)C(CSC2=CC=CC=C2)=CC(\C=C(/C#N)C(N)=O)=C1

InChI

InChIKey=YKLMGKWXBLSKPK-RIYZIHGNSA-N
InChI=1S/C19H18N2O3S/c1-2-24-17-10-13(8-14(11-20)19(21)23)9-15(18(17)22)12-25-16-6-4-3-5-7-16/h3-10,22H,2,12H2,1H3,(H2,21,23)/b14-8+

HIDE SMILES / InChI

Molecular Formula C19H18N2O3S
Molecular Weight 354.423
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7834843 | https://www.ncbi.nlm.nih.gov/pubmed/18077363 | https://www.ncbi.nlm.nih.gov/pubmed/1479375 | https://www.ncbi.nlm.nih.gov/pubmed/15744060

ST-638 (alpha-cyano-3-ethoxy-4-hydroxy-5-phenyl-methylcinnamamide) is a protein tyrosine kinase inhibitor that also inhibits HGF-induced MAP kinase activation in hepatocytes. ST638 has also shown to inhibit PC-PLD (phospholipase D) activity in human neutrophils and suppresses tyrosine phosphorylation induced by tumor necrosis factor-α and phorbol myristate acetate in neutrophils and by angiotensin II in cardiac fibroblasts.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

Rats were treated with ST-638 (30 or 100 mg/kg)
Route of Administration: Intraperitoneal
Rats hepatocytes were isolated by in vitro collagenase perfusion and low speed centrifugation. Cell viability was determined by trypan blue exclusion and ranged from 85 to 95%. The hepatocytes were cultured for 24 h in monolayers in a plastic dish (1x10^5 cells/cm2) in Williams’ medium E containing 10% fetal calf serum, 10 nM insulin, 10 nM dexamethasone and 5 KIU/ml aprotinin under 5%CO2 atmosphere. After removal of the medium by aspiration, monolayers of hepatocytes in the dish were further incubated for 0—90 min in Williams’ medium E containing 2% bovine serum albumin with or without the addition of heparin in the presence of ST-638 (1-5mM). The hepatocytes were harvested and centrifuged at 50xg for 5 min to remove cellular debris. The obtained supernatant served as the preparation for the released HTGL activity. HTGL activity was determined by a method using glycerol tri[1-14C]oleate (1.2mkM; 2.5 kBq/ml) as a substrate
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:10:04 GMT 2023
Edited
by admin
on Fri Dec 15 19:10:04 GMT 2023
Record UNII
6X89Y2007R
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ST-638
Common Name English
.ALPHA.-CYANO-(3-ETHOXY-4-HYDROXY-5-PHENYLTHIOMETHYL)CINNAMIDE
Common Name English
Code System Code Type Description
FDA UNII
6X89Y2007R
Created by admin on Fri Dec 15 19:10:04 GMT 2023 , Edited by admin on Fri Dec 15 19:10:04 GMT 2023
PRIMARY
EPA CompTox
DTXSID701147014
Created by admin on Fri Dec 15 19:10:04 GMT 2023 , Edited by admin on Fri Dec 15 19:10:04 GMT 2023
PRIMARY
CAS
107761-24-0
Created by admin on Fri Dec 15 19:10:04 GMT 2023 , Edited by admin on Fri Dec 15 19:10:04 GMT 2023
PRIMARY
PUBCHEM
5941457
Created by admin on Fri Dec 15 19:10:04 GMT 2023 , Edited by admin on Fri Dec 15 19:10:04 GMT 2023
PRIMARY